Allergy Treatment Market: Global Industry Analysis by Market Share, Trend, Size, Competitive Landscape, Regional Outlook and Forecast (2024-2030)

Global Allergy Treatment Market size was valued at USD 14.32 Bn in 2023 and is expected to reach USD 24.07 Bn by 2030, at a CAGR of 7.7 %

Allergies are immune system hypersensitivity reactions to chemicals that enter or come into contact with the human body. An allergen is a substance that induces an allergic response. Examples of allergic illnesses are Anaphylaxis, food allergies, asthma, conjunctivitis, eczema, eosinophilia disorders, and drug and insect allergies. Allergic diseases, rooted in complex interactions between genetics and the environment, encompass a range of systemic disorders like allergic rhinitis (AR), asthma, atopic dermatitis (AD), food allergies (FA), and eczema.

To know about the Research Methodology :- Request Free Sample Report

The World Health Organization identifies allergic diseases among the top disorders to prevent and control in the 21st century. With an estimated 500 million individuals affected by AR and 300 million by asthma globally, and rising cases, these conditions pose substantial health burdens. The pathogenesis of allergic diseases involves intricate immune responses, contributing to diverse clinical and pathological manifestations. From AR's nasal inflammation triggered by allergens to AD's skin barrier dysfunction, each condition demands tailored approaches. The history of allergic disease understanding, from ancient observations to modern breakthroughs, highlights advancements in treatment methods. Current strategies involve allergen avoidance, pharmacotherapy, and allergen-specific immunotherapy. As the incidence of allergic diseases continues to rise, a comprehensive market overview emphasizes the need for innovative treatments and interventions.

The escalating incidence of allergies, a significant public health challenge in developed nations, has tripled in the UK over the past two decades, rendering it among the worlds highest. Annually, 12 million individuals, constituting one-fifth of the UK population, seek allergy treatment. Unprecedented increases in life-threatening allergies, like peanut allergies affecting one in 70 children, underscore the urgency for effective healthcare solutions. However, the current system falls short in meeting even minimal care standards, lacking specialist allergists and clinical governance. Recognizing the imperative for change, the Royal College of Physicians advocates for urgent improvements, proposing increased consultant numbers, accessible centers nationwide, and enhanced training. This strategic overhaul aims to elevate allergy care on healthcare agendas, necessitating immediate attention and action from the Department of Health and healthcare planners.
Allergy Treatment Market Dynamics
The growing prevalence of allergies, a significant public health concern in developed nations, has tripled in the UK over the past two decades. With one-fifth of the UK population, around 12 million people, seeking allergy treatment annually, the country now grapples with one of the world's highest allergy rates. Notably, life-threatening allergies, previously rare, such as peanut allergies affecting one in 70 children, are on the rise. Despite the epidemic proportions, the current healthcare system fails to meet minimal care standards and lacks clinical governance.

The deficiency of specialist allergists exacerbates the issue, hindering direct care in dedicated allergy centers and impeding training for various healthcare professionals. The Royal College of Physicians emphasizes the necessity for recognizing and treating milder allergy cases in primary care, reserving referrals to consultants for severe and complex cases. Urgent action is imperative to address the escalating needs of allergy patients. The proposed improvements include increased consultant numbers, the establishment of accessible allergy centers nationwide, and enhanced training for healthcare providers. This comprehensive strategy aims to elevate the importance of allergy treatment on the healthcare agenda, requiring immediate attention from the Department of Health and healthcare planners and managers.

Rising self-medication cases, rising healthcare expenditure, an aging population, an increase in the number of government-sponsored awareness programs, and rising incidences of chronic diseases are expected to propel the allergy treatment market forward over the forecast period. Increasing R&D and increased knowledge of immunotherapy for the treatment of allergies among healthcare professionals and patients, on the other hand, are expected to provide profitable opportunities in the future.

Increasing Preference for Self-Medication for Allergy Treatment to Boost Market

Aeroallergens include tree weed, wheat, dust mite, soy, mold, prawns, eggs, and a variety of other food and non-edible items. Allergens can cause allergic rhinitis, asthma, hay fever, and atopic dermatitis, among other allergic diseases. Allergic reactions can include rashes, itching in the nose, eyes, and throat, stuffy nose, red and teary eyes, sneezing, and other symptoms. Aside from respiratory symptoms, allergies to particular foods can cause severe diarrhea, vomiting, and respiratory problems. It may potentially result in death, however, this is an uncommon occurrence.

The World Allergy Organization (WAO), comprising 92 regional and national allergology and clinical immunology societies globally, serves as a pivotal force in the field. These societies offer a wealth of knowledge and expertise, making them invaluable resources. To enhance patient care for allergic diseases, it is highly recommended that public health authorities, government officials, medical school leaders, and patient groups collaborate with these societies. Leveraging the collective insight of WAO members, including regional and national allergy, asthma, and clinical immunology societies, is crucial. Their contribution to WAO Councils and readiness to assist with inquiries position them as key collaborators in implementing effective recommendations within the market.

Unprecedented Surge in Allergies Transforming Healthcare and Driving Market Growth

Allergies have emerged as a formidable driver within the healthcare industry, especially in developed nations like the UK. Witnessing a staggering threefold increase in common allergic diseases, the UK now stands at the forefront globally, grappling with one of the highest allergy rates. Annually, a whopping 12 million individuals—equivalent to one-fifth of the population actively seek treatment for allergies, signifying a substantial and rapidly growing market. This surge isn't confined to common allergies alone; even potentially life-threatening but previously rare conditions, such as peanut allergies affecting one in 70 children, are experiencing a notable uptick. However, despite the epidemic proportions of this health concern, the current healthcare system falls significantly short of meeting even the most basic care standards, let alone ensuring robust clinical governance.

The crux of the issue lies in the acute shortage of specialist allergists, impeding the establishment of dedicated allergy centers and the provision of essential training for various healthcare professionals. The demand for streamlined care pathways is evident milder allergy cases should ideally be identified and treated within primary care settings, while severe and complex cases necessitate referral to specialized consultants. Regrettably, the absence of requisite infrastructure and training obstructs this approach, resulting in a perpetual failure to meet the burgeoning needs of allergy patients. allergy treatment higher on the healthcare agendas of influential bodies such as the Department of Health, planners, and managers. The proposed solutions promise a revamped and much-improved allergy service, contingent upon a commitment to change and a deep understanding of the challenges faced by allergy patients. Implementation would lead to an influx of consultants, the establishment of accessible centers nationwide, and an extensive enhancement in the training provided to healthcare providers. Urgent action is imperative to harness this burgeoning market and cater effectively to the pressing needs of allergy patients.

Restraints in the Allergy Treatment Market

The complexity of allergic disorders, marked by intricate gene-environment interactions, presents a significant hurdle in predicting disease onset, severity, and treatment response. Despite advancements in genetic studies, polymorphisms of a single gene offer limited insight, and risk scores from multiple loci remain insufficient. Epigenetic influences and trans-generational effects add layers of complexity, necessitating careful replication in large, well-characterized populations. Collaborative efforts across academia, industry, and clinical practice are imperative but challenging to establish. Sensitization to common allergens, affecting 40% of the population, further complicates treatment strategies. Indoor and outdoor pollution, linked to increased respiratory diseases globally, poses substantial health risks, with exposure-associated mortality demanding urgent attention. Socioeconomic disparities contribute to the unequal burden of allergic diseases, requiring heightened awareness and intervention to address environmental risk factors.

Challenges in Allergy Treatment Market

The escalating prevalence of asthma and allergies, coupled with socio-economic disparities, underscores the formidable challenges in the allergy treatment market. The complexity of gene-environment interactions and limited predictability from genetic studies inhibit the development of precise treatments. Sensitization to allergens, affecting a significant portion of the population, adds variability to therapeutic approaches. Widespread indoor and outdoor pollution, linked to respiratory diseases and mortality, demands urgent attention for effective mitigation. Socio-economic factors contribute to disparities in disease burden, requiring focused research to address environmental risks. Climate change and migration introduce additional complexities, impacting allergic conditions and necessitating adaptive healthcare strategies. Overcoming these challenges demands collaborative efforts across diverse sectors to enhance the precision and efficacy of allergy treatment.
Allergy Treatment Market Trends
The atopic diseases across Western Europe, the US, and Australasia highlights the profound impact of environmental influences on allergy prevalence. Notable shifts, like the rise in seasonal allergic rhinitis and asthma after the unification of Germany, suggest environmental rather than genetic drivers. A 'Westernized lifestyle,' characterized by cleaner surroundings and antibiotic use, is implicated in immune system alterations, depriving it of microbial antigens that stimulate Th1 cells. Epidemiological studies link atopy protection to exposure to microbes from farming or older siblings. However, challenges emerge, with instances of atopic asthma among poor urban populations, indicating the complexity of environmental factors. In the allergy treatment market, addressing these diverse trends necessitates innovative approaches tailored to evolving environmental dynamics.
Allergy Treatment Market Segmentation Analysis
By Allergy Type,
In 2023, the allergy treatment market is categorized into Respiratory Allergies, Food Allergies, Skin Allergies, Eye Allergies, and Others. Among these respiratory allergies, is dominates the market during the forecast period, especially rhinitis and asthma. This prominence is rooted in their staggering global prevalence, affecting over 1 billion individuals. Unlike certain food allergies, respiratory allergies often necessitate continual symptom management, ensuring a sustained demand for treatments. The accessibility of a diverse range of effective medications and devices further contributes to their market dominance. the economic footprint of respiratory allergies, particularly asthma, is substantial, with an annual societal cost of USD 21 billion in the US alone. These factors collectively establish respiratory allergies as the frontrunner in the current landscape of the allergy treatment market. This was ascribed to an increase in the global prevalence of allergic rhinitis. According to the European Academy of Allergy and Clinical Immunology (EAACI), rhinitis affected over 560 million individuals globally in 2023.

By Treatment Type,
In the allergy treatment market, medication is the most dominating segment in 2023 Medications offer immediate relief and symptom management for a wide range of allergies, making them a popular choice among patients. Antihistamines, corticosteroids, and decongestants address symptoms effectively, catering to the large population seeking quick and accessible remedies. Immunotherapy, although highly effective in addressing the root cause of allergies, requires a longer duration for noticeable results, limiting its widespread adoption. Allergen avoidance strategies, while crucial, often prove challenging due to the ubiquity of allergens. Medication's swift relief and widespread availability position it as the dominant choice, meeting the immediate needs of allergy sufferers in the market.

By Distribution Channel,
In the allergy treatment market, retail pharmacies held the largest market share in 2023 due to their accessibility, coupled with a wide array of over-the-counter and prescription allergy medications, making them the primary choice for consumers seeking immediate relief. Retail pharmacies offer convenience, allowing patients to access treatments swiftly without the need for appointments or prescriptions in some cases. Online pharmacies are gaining traction due to convenience, but concerns about authenticity and regulation limit their dominance. Hospital and doctor's office channels primarily cater to severe cases or specific treatments, thus occupying a smaller share. The widespread presence, convenience, and diverse range of medications position retail pharmacies as the leading channel in meeting the demands of allergy sufferers in the market.
Allergy Treatment Market Regional Insight:
In 2023, North America held a market share of 37.30 percent of the global allergy treatment market. Geographically, North America is the largest sector of the global allergy treatment market. The increasing incidence of allergies in the area, the mature market, increased knowledge of allergic disorders, and expanding risk factors related to allergies have all contributed to the region's rise. Both the United States and Canada are developed economies with significant per capita healthcare spending. Both Countries have been overhauling their healthcare systems to make them more patient-centered, resulting in increased knowledge of personal health and disorders.

North America has a high level of awareness of allergic disorders, which has contributed to the region's allergy treatment market. Immunotherapies, as well as epinephrine auto injectors and inhalers, have increased the adoption of innovative medicines and medical devices for allergy control. According to the American Academy of Allergy, Asthma, and Immunology, about 27.2 million persons in the United States have allergic rhinitis with another 26 million having asthma. This strong demand is expected to keep North America as the most profitable area for allergy treatment shareholders in the world.

In addition to the United States, Canada's government is concentrating on giving Canadians the knowledge they need to make healthy and safe food choices. To achieve this aim, the CFIA (Canadian Food Inspection Agency) and Health Canada collaborate with provincial, municipal, and territorial partners as well as sectors. Furthermore, multiple medications are being developed in the United States, especially to treat various forms of allergies. Players in the market are concentrating their efforts on the development and introduction of new products. The US Food and Drug Administration approved Immune Therapeutics Inc.'s Biologics License Treatment Type (BLA) for AR101 for assessment in March 2019. (FDA). During the forecast period, the US allergy treatment market is expected to increase due to an emphasis on R&D, especially for the launch of improved products.

Another region quickly gaining importance is the global allergy treatment market in Asia-Pacific. The progressive growth of the healthcare infrastructure, as well as greater awareness of advanced immunotherapy in allergy treatment, are reasons for its rising significance. The growing number of firms delivering immunotherapies across the region is one of the key reasons driving the rise of allergy treatment. Allergic rhinitis affects about 45 percent of the population in Europe between the ages of 20 and 45, and advances in allergy therapy are fueling this growth.

The escalating prevalence of atopic diseases in recent years, particularly in Western Europe, the US, and Australasia, underscores the pivotal role of environmental influences. A notable example illustrating the impact of environmental changes is observed in the post-unification scenario of Germany. While atopic disorders were less common in East Germany before unification, a subsequent rise in atopy and hay fever prevalence, particularly in children raised in East Germany, suggests a shift linked to a 'Westernized lifestyle.' Epidemiological studies across regions like Estonia and Sweden provide insights into microbial colonization of the gastrointestinal tract influencing atopic sensitization. Estonia, with its predominance of Lactobacilli and Eubacteria, exhibits lower atopy rates than Sweden, where Clostridia are more frequent. Further support for environmental influences on atopic diseases comes from regions with specific exposures, such as farming lifestyles in Europe and Africa, protecting atopic disease development. factors like birth dates coinciding with pollen seasons, alterations in the infant diet, and repeated immune stimulation through exposures in early childhood influence the Th2 phenotype and offer protection against atopic allergic diseases.

Apparent inconsistencies, such as the increased prevalence of atopic asthma among poor Blacks in the US, are associated with sensitization to cockroaches and house dust mites. Inner-city dwellers may face the compounding effects of inadequate gut flora protection and heightened allergen exposure, contributing to this paradox. The development of specific allergic diseases is intricately linked to alterations in target organs, with factors like respiratory virus infections, increased allergen exposure, tobacco smoke, and air pollutants playing a role in promoting Th2 cell-mediated allergic inflammatory responses. This regional analysis emphasizes the dynamic interplay of environmental factors and individual susceptibility in shaping the prevalence of atopic diseases across different regions.

The report also helps in understanding the Allergy Treatment Market dynamics, and structure by analyzing the market segments and projecting the Allergy Treatment Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Allergy Treatment Market make the report an investor’s guide.

Allergy Treatment Market Competitive Analysis

The allergy treatment market is intensely competitive, driven by the increasing prevalence of allergies and the demand for innovative therapies. Key players such as GlaxoSmithKline, Johnson & Johnson (J&J), Sanofi SA, AbbVie Inc. (Allergan), and ALK-Abello dominate the market, leveraging their extensive product portfolios and global presence. These companies focus on strategic collaborations, mergers, and acquisitions to expand their market share and enhance their product offerings.

The emergence of biologics, such as monoclonal antibodies, has revolutionized allergy treatment, and companies like Roche and Sanofi are at the forefront of this development. Advancements in immunotherapy, particularly sublingual and subcutaneous allergen immunotherapy, contribute to the competitive landscape, with Staller genes Greer and ALK-Abele being notable players. pharmaceutical giants, smaller firms like DBV Technologies and Circassia Pharmaceuticals are gaining prominence, emphasizing niche markets and specialized therapies. The market also witnesses increased research and development activities, with companies investing in novel drug formulations and personalized medicine approaches.

The competitive dynamics in the allergy treatment market are shaped by regulatory approvals, product efficacy, safety profiles, and pricing strategies. As the quest for more effective and targeted allergy treatments continues, players in the market must adapt swiftly to technological advancements and evolving patient needs to maintain a competitive edge.
Allergy Treatment Market Scope: Inquire before buying



Global Allergy Treatment Market


Report Coverage
Details


Base Year:
2023
Forecast Period:
2024-2030


Historical Data:
2018 to 2023
Market Size in 2023:
US $ 14.32 Bn.


Forecast Period 2024 to 2030 CAGR:
7.7%
Market Size in 2030:
US $ 24.07 Bn.


 Segments Covered:
by Allergy Type
Respiratory Allergies
Food Allergies
Skin Allergies
Eye Allergies
Other


by Treatment Type
Medication
Immunotherapy
Allergen avoidance


by Distribution Channel
Hospital pharmacies
Retail pharmacies
Online pharmacies
Direct-to-consumer sales
Doctor's offices



Allergy Treatment Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
South America (Brazil, Argentina Rest of South America)
Middle East & Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
Allergy Treatment Key players
Europe
1. Allergopharma- Germany
2. Allergy Therapeutics - United Kingdom
3. Alerpharma S.A - Spain
4. Allergon AB - Sweden
6. Sanofi – France
7. Allergan, Inc. - Ireland
North America
1. Genentech Inc. - United States
2. McNeil Consumer Healthcare - United States
3. Schering-Plough Corporation - United States
4. Meda Pharmaceuticals, Inc. - United States
5. Collegium Pharmaceutical, Inc. - United States
6. Vicks, and Sepracor, Inc. - United States
7. Johnson & Johnson Services Inc - United States
8. Mylan N.V. - United States
Asia
1. Cipla Inc - India
2. Aurobindo Pharma - India
3. Zydus Cadila - India
4. Lupin - India
5. Dr. Reddy's Laboratories Ltd - India
Middle East:
1.Teva Pharmaceutical Industries Ltd - Israel
2.Switzerland
3.Novartis AG - Switzerland

Frequently Asked Questions:

1] What is the growth rate of the Global Allergy Treatment Market?
Ans. The Global Allergy Treatment Market is growing at a significant rate of 7.7 % during the forecast period.

2] Which region is expected to dominate the Global Allergy Treatment Market?
Ans. North America is expected to dominate the Allergy Treatment Market during the forecast period.

3] What is the expected Global Allergy Treatment Market size by 2030?
Ans. The Allergy Treatment Market size is expected to reach USD 24.07 Bn by 2030.

4] Which are the top players in the Global Allergy Treatment Market?
Ans. The major top players in the Global Allergy Treatment Market are Allergopharma, Allergy Therapeutics, Alerpharma S.A, Allergon AB, Genentech Inc., and Allergan, Inc.

5] What are the key driving factor for the growth of Market?
Ans- Rising self-medication cases, rising healthcare expenditure, an aging population, an increase in the number of government-sponsored awareness programs, and rising incidences of chronic diseases are expected to propel the allergy treatment market forward over the forecast period.6] Which country held the largest Global Allergy Treatment Market share in 2023?